Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Mio

Nakamura

,

MD, MS, FAAD

Assistant Professor
University of Michigan
Ann Arbor
,
Michigan
,
United States
2023 Fellow
IPC Jr. Councilor
Request an Update
Dr. Mio Nakamura is an Assistant Professor and the Director of the Program for Clinical Research in Dermatology in the Department of Dermatology at the University of Michigan. She completed a clinical research fellowship at the University of California, San Francisco, before completing her dermatology residency at the University of Michigan. She also holds a Master’s in Clinical Research Design and Statistical Analysis from the University of Michigan School of Public Health. Dr. Nakamura’s clinical and research interests include chronic inflammatory skin conditions, such as psoriasis, atopic dermatitis, prurigo nodularis, and autoimmune skin conditions, such as cutaneous lupus. She conducts sponsored and investigator-initiated clinical trials in these areas and works closely with scientists on clinical aspects of translational studies. During her IPC Fellowship, Dr. Nakamura studied with IPC Councilor Nick Reynolds at Newcastle University, Newcastle upon Tyne, United Kingdom.
Last Updated:
06/26/2025

Areas of Interest

New therapies; Clinical trials; Quality of life; Disparities

IPC Committees / Groups

Diverse Skin Types Working Group

Languages Spoken

English

Involvement with Other Organization(s)

Dr. Nakamura is a Scientific Advisory Committee member for the National Psoriasis Foundation (NPF), United States.
Recent publications

Featured

Page

Challenging Patient Interactions: What's Really Behind the 'Difficult' Label — A Conversation with Dr. John Koo.

IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality…

View Report

Page

Approaching Challenging Patient Interactions with Empathy.

IPC Jr. Councilor Mio Nakamura discusses how personality traits and emotional dynamics can affect clinical…

View Report

Video

Psoriasis and Mental Health.

In this Take Ten with IPC video, IPC Junior Councilor Dr. Mio Nakamura provides an overview of psoriasis and its impact…

Watch Video

Video

Case Presentation: Psoriasis and Depression.

2023 IPC Fellow Dr. Mio Nakamura presents a challenging case on a patient with psoriasis and depression.

Watch Video

PDF

A Report from the 2025 American Academy of Dermatology (AAD) Annual Meeting.

The 2025 AAD Annual Meeting featured important updates on psoriasis therapies, comorbidities, and late-breaking…

View Report

PDF

Psoriasis in People With Skin of Color: An Evidence-Based Update.

This article provides an evidence-based update on psoriasis in individuals with skin of color (SOC), highlighting…

View Report

Blog

A Year in the Life of IPC’s 2023 International Fellows.

Explore the global dermatological journey of the 2023 IPC International Fellows. Learn about their diverse experiences,…

Read More

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026